<DOC>
	<DOCNO>NCT01728233</DOCNO>
	<brief_summary>Penile squamous cell carcinoma ( SCC ) rare disease prognosis depend primarily regional lymph-node involvement . Despite fact cure obtain patient low metastatic load ( pN1 ) monotherapy , combination therapy require advanced case . Medical treatment option advance metastatic penile SCC effective far chance cure solely dependent multimodality treatment , either surgery radiation . Based observation epidermal growth factor receptor ( EGFR ) almost invariably express penile SCC assume similarity SCC head neck district , anti-EGFR target monotherapy investigate promising early result Istituto Tumori Milan University Texas MD Andreson Cancer Center . These premise lend support use pan-HER inhibitor dacomitinib advance metastatic penile SCC .</brief_summary>
	<brief_title>Dacomitinib ( PF-00299804 ) Advanced/Metastatic Squamous Cell Carcinoma Penis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Penile Neoplasms</mesh_term>
	<criteria>Patients must provide write informed consent Eastern Cooperative Oncology Group performance status least 1 Cytologically histologically proven diagnosis SCC penis Uni bidimensionally measurable disease define RECIST v1.1 criterion Clinical stage N23 and/or M1 ( TNM 2002 ) Locoregional relapse prior major surgery/ies ( either single multiple ) No prior systemic therapy except administration vincristinebleomycinmethotrexate ( VBM ) chemotherapy superficial disease administer least 6 month prior study enrollment Adequate bone marrow , liver renal function Central nervous system ( CNS ) metastases leptomeningeal carcinomatosis History active serious cardiovascular , cerebrovascular , pulmonary comorbidities Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma cancer curatively treat &gt; 5 year prior study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Molecular Targeted Therapy</keyword>
	<keyword>Neoadjuvant therapy</keyword>
	<keyword>Dacomitinib</keyword>
</DOC>